]11[]21[
140930
‫תרכובות והרכבים עבור אספקת חומרים‬
‫פעילים‬
]54[
COMPOUNDS AND
COMPOSITIONS FOR
DELIVERING ACTIVE AGENTS
]22[
]31[
06.08.1999
60/095778
]32[ 07.08.1998
]33[ US
60/098500
31.08.1998
US
60/108366
13.11.1998
US
60/119207
05.02.1999
US
Int. Cl.8 A61K 009/00, 047/16, C07C 235/24, 235/44, 237/36
EMISPHERE TECHNOLOGIES, INC.,
U.S.A.
WO/2000/007979
SANFORD T.COLB & CO.,
,,'‫ קולב ושות‬.‫סנפורד ט‬
P.O.B. 2273,
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
REHOVOT
]51[
]71[
]87[
]74[
[57] A compound selected from the group
consisting of:
1125
July 5, 2006– ‫ט' בתמוז התשס"ו‬
__________
]11[]21[
]54[
VIDEO CONFERENCING
INTERFACE
]22[
]31[
]51[
]71[
]87[
]74[
27.07.1999
60/094646
]32[ 30.07.1998
Int. Cl.8 H04N 007/14
SORENSON VISION, INC., U.S.A.
WO/2000/007371
WOLFF, BREGMAN AND GOLLER,
19B KEREN HAYESOD ST.
P.O.B. 1352,
JERUSALEM 91013
[57] A video conferencing circuit for use
with a plurality of video input devices and
a video output device, said video
conferencing circuit comprising: video
input means configured to select an input
video signal from one of a plurality of
video signal generating devices, said video
input means including a video decoder
circuit to receive selected video signals
and convert said selected video signals to
an input video signal; a remote interface
circuit; a video output device, and an
application specific integrated circuit
(ASIC) connected to said video input
means, to said video output device and to
July 5, 2006– ‫ט' בתמוז התשס"ו‬
141005
‫ממשק לועידת חוזי‬
]33[
US
,‫ ברגמן וגולר‬,‫וולף‬
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
said remote interface circuit, said ASIC
having: a high speed serial video input, a
video-in circuit connected to said video
input means to receive one of said input
video signals from one of said plurality of
video signal generating devices and said
high speed serial video input, said video-in
circuit including an input configuration
circuit connected to receive one of a
plurality of video input signals and a high
speed serial video input, a control register
connected to said video processing means
to receive control signals therefrom and
said input configuration circuit to supply
input control signals to cause said input
1126
configuration circuit to operate to supply
said one of said plurality of video input
signals as said input video signal to said
memory circuit, a memory circuit
connected to said video-in circuit to
receive said one of said input video signal
and said high speed serial video input, said
memory circuit being configured to retain
and transmit said one of said input video
signal and said high speed serial video
input as stored data, data compression
means connected to said memory circuit to
receive said stored data and to compress
said stored data through an encoding
process to form outgoing compressed data,
video processing means connected to
receive said outgoing compressed data and
connected to said remote interface circuit
to transmit said outgoing compressed data
and to receive incoming compressed data
from a remote station, video
decompression means connected to said
video processing means to receive said
incoming compressed data and configured
to decompress and to transmit said
incoming compressed data to said memory
circuit, said memory circuit being
configured to convert said incoming
compressed data to incoming stored data,
and video image out means connected to
receive incoming stored data from said
memory circuit and to transmit said
incoming stored data as a video image
signal to a video display device, wherein
said memory circuit includes a memory
structure and a memory control circuit to
convert said one of said input video signal
and said high speed serial video input to
stored data and to convert said incoming
compressed data to incoming stored data,
and wherein said output of said input
configuration circuit is supplied to a
decimation circuit which operates to
reduce the density of the said output signal
and is connected to a buffer to store and
transmit an output which is a video, and
wherein said video processing means is
connected to said video-in circuit, said
memory circuit, said video decompression
means, said data compression means, and
to said video image out means to control
the flow of video signals therein between.
__________
1127
July 5, 2006– ‫ט' בתמוז התשס"ו‬
]11[]21[
]54[
WORLD WIDE WEB ACCESS FOR
VOICE MAIL AND PAGE
]22[
]31[
]51[
]71[
29.07.1999
127562
]32[ 31.07.1998
Int. Cl.8 G06F 013/00, 019/00
GLENAYRE ELECTRONICS, INC.,
U.S.A.
WO/2000/007109
REINHOLD COHN AND
PARTNERS,
21 AHAD HA'AM ST.,
P.O.BOX 4060,
TEL AVIV 61040
]87[
]74[
[57] An integrated message processing
system, comprising:
(a) a management component including at
least one server, wherein said management
component manages a plurality of types of
messages;
(b) a self-hosting user interface component
for displaying and manipulating the
plurality of types of messages;
(c) a remote client on which the selfhosting user interface component is to be
stored and executed such that the remote
client, via the self-hosting user interface
July 5, 2006– ‫ט' בתמוז התשס"ו‬
141042
‫גישה דרך רשת האינטרנט לדואר קולי‬
]33[
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
component, controls the processes of
displaying and manipulating the plurality
of types of messages;
(d) a communications media, wherein said
communications media facilitates
communications between said remote
client and said self-hosting user interface
and management components; and
(e) a transmission media, wherein said
self-hosting user interface component is
transmitted to said remote client over said
communications media via said
transmission media.
1128
__________
]11[]21[
141083
‫תרופות של מעכבי פרוטונים‬-‫קדם‬
]54[
PRODRUGS OF PROTON PUMP
INHIBITORS
]22[
]31[
09.08.1999
09/131481
]32[ 10.08.1998
]33[ US
09/364381
29.07.1999
US
Int. Cl.8 A61K 031/395, A61P 043/00, C07D 213/60, 215/16, 235/28, 239/72,
241/40, 263/16, 277/60, 401/12, 403/12, 413/12, 471/04
WINSTON PHARMACEUTICALS,
LLC., U.S.A.
REGENTS OF THE UNIVERSITY OF
CALIFORNIA, U.S.A.
U.S. GOVERNMENT,
REPRESENTED BY THE
DEPARTMENT OF VETERANS
AFFAIRS, U.S.A.
WO/2000/009498
EITAN, PEARL, LATZER AND
,‫ לצר וכהן צדק‬,‫ פרל‬,‫איתן‬
COHEN ZEDEK,
‫ הרצליה‬,12688 .‫ד‬.‫ ת‬, 7 ‫רחוב שנקר‬
P.O.B. 12688,
HERZLIYA 46733
]51[
]71[
]87[
]74[
1129
July 5, 2006– ‫ט' בתמוז התשס"ו‬
[57] A compound of the formula
Het1 – X – S(O) – Het2
wherein
Het1 is selected from the group of the formulas
X is selected from the group of the formulas
and Het2 is selected from the group
consisting of the formulas
where N in the benzimidazole moiety
represents that one of the ring carbons may
be exchanged for an unsubstituted N atom;
R1, R2 and R3 are indepdentnly selected
from hydrogen, alkyl of 1 to 10 carbons,
fluoro substituted alkyl of 1 to 10 carbons,
alkoxy of 1 to 10 carbons, fluoro
substituted alkoxy of 1 to 10 carbons,
alkylthio of 1 to 10 carbons, fluoro
substituted alkylthio of 1 to 10 carbons,
alkoxyalkoxy of 2 to 10 carbons,
alkylamino and dialkylamino each of the
alkyl groups in said alkylamino and dialkyl
amino groups having 1 to 10 carbons,
July 5, 2006– ‫ט' בתמוז התשס"ו‬
halogen, phenyl, alkyl substituted phenyl,
alkoxy substituted phenyl, phenylalkoxy,
each of the alkyl groups in said alkyl
substituted phenyl, alkoxy substituted
phenyl and phenylalkoxy having 1 to 10
carbons, piperidino, morpholino or two of
the R1, R2 and R3 groups jointly forming a
5 or 6 membered ring having 0 or 1
heteroatom selected from N, S and O;
R4 and R5 are independently selected from
hydrogen, alkyl of 1 to 10 carbons, fluoro
substituted alkyl of 1 to 10 carbons,
phenylalkyl, naphthylalkyl and
heteroarylalkyl, alkyl in said phenylalkyl,
1130
naphthylalkyl and heteroarylalkyl groups
having 1 to 10 carbons; R6 is hydrogen,
halogen, alkyl of 1 to 10 carbons, fluoro
substituted alkyl of 1 to 10 carbons, R6
through R9 are independently selected
from hydrogen, alkyl of 1 to 10 carbons,
halogen, substituted alkyl of 1 to 10
carbons, alkoxy of 1 to 10 carbons,
halogen substituted alkoxy of 1 to 10
carbons, alkylcarbonyl, alkoxycarbonyl,
the alkyl group in said alkylcarbonyl and
alkoxycarbonyl having 1 to 10 carbons,
oxazolyl, imidazolyl, thiazolyl, pyrazolyl,
or any two adjacent ones of the R6 through
R9 groups may form a ring that may
optionally include a heteroatom selected
from N, O and S; R10 is hydrogen, alkyl of
1 to 10 carbons; R11 and R12 are
independently selected from hydrogen,
halogen, alkyl of 1 to 10 cabons and
halogen substituted alkyl of 1 to 10
carbons; R15 has the formula
where
R17 is alkyl of 1 to 10 carbons, halogen
substituted alkyl of 1 to 10 carbons, alkoxy
having 1 to 10 carbons, halogen substituted
alkoxy of 1 to 10 carbons, alkylthio having
1 to 10 carbons, halogen, substituted
alkylthio of 1 to 10 carbons, alkoxy
carbonyl having 1 to 10 carbons, halogen
substituted alkoxy carbonyl having 1 to 10
carbons, F, Cl, Br, I, NO2, CN, OCOalkyl,
NH2, alkylamino and dialkylamino where
in said OCOalkyl, alkylamino and
dialkylamino groups each of said alkyl
groups has 1 to 10 carbons, carbamoyl, Nsubstituted carbamoyl, alkylcarbonyl
having 1 to 10 carbons, (alkoxycarbonyl)
alkoxy groups of each of said alkoxy group
has 1 to 10 carbons, (alkoxycarbonyl) alkyl
groups of each of said alkoxy or alkyl
group has 1 to 10 carbons, (carbamoyl)
alkoxy having 1 to 10 carbons, (Nalkylcarbamoyl) alkoxy having 1 to 10
carbons, (N, N-dialkylcarbamoyl) alkoxy
having 1 to 10 carbons, (N-substituted or
unsubstituted carbamoyl) poly (alkoxy)
having 1 to 10 carbons, (N-substituted or
unsubsituted carbamoyl) alkyl having 1 to
10 carbons, [N-(heteroaryl) carbamoyl]
alkyl having 1 to 10 carbons, [N(heteroaryl) carbamoyl] alkoxy having 1 to
10 carbons, [N-(substituted heteroaryl)
carbamoyl] alkoxy having 1 to 10 carbons,
[N-(substituted aryl) carbamoyl] alkoxy
having 1 to 10 carbons, poly (alkoxy)
group of each of said alkoxy group has 1 to
10 carbons, cyclic polyalkoxy, guanidinyl
group, ureido group, dialkylamino-poly
(alkoxy) group, [N-(carbamoylalkyl)
carbamoyl] alkoxy, [N-(carbamoylalkyl)
carbamoyl] alkyl, [N-[[N-(heteroaryl)
carbamoyl] alkyl] carbamoyl] alkoxy, [N[[N-(substituted heteroaryl) carbamoyl]
alkyl] carbamoyl] alkoxy, (sulfonato)
alkyl, (sulfonato) alkoxy, N-[sulfonato)
alkyl] amido, (substituted) maleimido-,
(substituted) succinimido [(tri-alkyl)
ammonium]-alkoxy, and
R21 is (aryl) alkyl, (heteroaryl) alkyl,
phenyl, naphthyl or heteroaryl where
heteroaryl has 1 to 3 heteroatoms
independently selected from N, O and S,
said phenyl, naphthyl or heteroaryl groups
being unsubstituted or substituted with 1 to
5 R17 groups, or to a pharmaceutically
acceptable salt of said compound.
__________
1131
July 5, 2006– ‫ט' בתמוז התשס"ו‬
]11[]21[
141104
‫גישה מרוחקת למחשב‬
]54[
REMOTE COMPUTER ACCESS
]22[
]51[
]71[
]87[
]74[
27.07.1998
Int. Cl.8 G06F 019/00, H04L 012/00, H04N 007/10
WEBTV NETWORKS, INC., U.S.A.
WO/2000/007091
WOLFF, BREGMAN AND GOLLER,
,‫ ברגמן וגולר‬,‫וולף‬
19B KEREN HAYESOD ST.
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
P.O.B. 1352,
JERUSALEM 91013
[57] A method of remote computer
access, comprising: executing a program at
a first location, to generate display
commands; converting said display
commands directly into a compressed
video data stream without rendering said
display commands; transmitting said
The applications for
division from this
application have not yet
been published
compressed data stream to a second
location, remote from said first location;
decompressing said compressed data
stream at the second location, and
displaying the decompressed data stream
as an image at the second location.
,173679,173678,173677,173676
‫בקשות חלוקה מבקשה זו‬
.‫שטרם פורסמו‬
_________
July 5, 2006– ‫ט' בתמוז התשס"ו‬
1132
]11[]21[
]54[
TREATMENT OF PIGMENTED
TISSUES USING OPTICAL
ENERGY
]22[
]31[
]51[
]71[
]87[
]74[
29.07.1999
130213
]32[ 06.08.1998
Int. Cl.8 A61B 018/00, 018/20
PHOTOGEN, INC., U.S.A.
WO/2000/007514
SELIGSOHN GABRIELI LEVIT &
CO.,
31 YAVNE ST.
P.O.B. 1426
TEL AVIV 61013
[57] A method for the treatment of a
particular volume of tissue, said volume of
tissue containing an endogenous pigment,
the method comprising the steps of:
treating the particular volume of tissue
141243
‫טיפול ברקמות עם פיגמנטים בשימוש‬
‫אנרגיה אופטית‬
]33[
US
,'‫זליגסון גבריאלי לויט ושות‬
‫ תל אביב‬,1426 .‫ד‬.‫ ת‬, 31 ‫רח' יבנה‬
with light to promote thermal overload of
pigmented cells in the particular volume of
tissue, wherein said thermal overload kills
said pigmented cells.
__________
]11[]21[
141314
‫שיטה וציוד עבור קבלת איתות ממערכת‬
‫מיקום לווינית‬
]54[
METHOD AND APPARATUS FOR
ACQUIRING SATELLITE
POSITIONING SYSTEM SIGNALS
]22[
]31[
]51[
]71[
25.03.1997
132556
]32[ 11.08.1998
]33[ US
Int. Cl.8 G01S 005/00, 005/14, H04B 007/185, H04Q 007/20
SNAPTRACK INCORPORATED,
U.S.A.
WO/2000/036431
SANFORD T.COLB & CO.,
,,'‫ קולב ושות‬.‫סנפורד ט‬
P.O.B. 2273,
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
REHOVOT
]87[
]74[
[57] A method for reducing search time
to acquire satellite positioning system
(SPS) signals in a satellite positioning
system receiver, said method comprising;
determining a first pseudorange to a first
SPS satellite; determining an approximate
location of said SPS receiver; determining
1133
an estimated pseudorange for a second
pseudorange to a second SPS satellite,
said estimated pseudorange being
determined from said approximate location
and said first pseudorange; searching for
time of arrival of SPS signals from said
July 5, 2006– ‫ט' בתמוז התשס"ו‬
second SPS satellite in a range determined
by said estimated pseudorange.
__________
]11[]21[
]54[
PACKAGE FOR IMPROVED
STABILITY FOR INJECTION
SOLUTIONS
]22[
]31[
]51[
]71[
]72[
24.08.1999
9802938-2
]32[ 01.09.1998
Int. Cl.8 A61J 001/05
ASTRAZENECA AB, SWEDEN
LUNDGREN ANNA, SUNDGREN
MATS
WO/2000/012043
LUZZATTO & LUZZATTO,
P.O.B 5352
BEER-SHEVA 84965
]87[
]74[
[57] A primary package containing an
aqueous solution for parenteral
administration comprising a low molecular
weight peptide-based thrombin inhibitor or
141333
‫צרור ליציבות משופרת לתמיסות הזרקה‬
]33[
SE
,‫לוצאטו את לוצאטו‬
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשיה‬
a salt thereof and having a pH in the range
of 3 to 8, wherein the primary package is
sealed with a rubber stopper or plunger
containing bromobutyl rubber.
_________
]11[]21[
July 5, 2006– ‫ט' בתמוז התשס"ו‬
141359
1134
]54[
METHOD OF MANUFACTURE OF
1,3-OXATHIOLANE
NUCLEOSIDES
]22[
]31[
12.08.1999
60/096214
]32[ 12.08.1998
60/122841
04.03.1999
Int. Cl.8 C07D 327/00, 327/04
EMORY UNIVERSITY, U.S.A.
GILEAD SCIENCES, INC., U.S.A.
]51[
]71[
]87[
]74[
‫ אוקסאתיאולאן‬3,1 ‫שיטה ליצורם של‬
‫נוקלאוזידים‬
]33[
WO/2000/009494
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.BOX 4060,
TEL AVIV 61040
US
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
,173745
The applications for division
from this application have
not yet been published
[57] A process for preparing 2(R1C(O)OCH2)-1, 3-oxathiolanyl-5-one by
directly reacting an acetal of the formula
(R1O)2CHR wherein R is –(CH2-OC(O)R2), wherein R1 and R2 are
‫בקשות חלוקה מבקשה זו‬
.‫שטרם פורסמו‬
independently alkyl, aryl, heteroaryl,
heterocyclic, alkaryl, alkylheteroaryl, or
alkylheterocyclic, or aralkyl, with
mercaptoacetic acid in an organic solvent.
__________
]11[]21[
]54[
METHOD AND APPARATUS FOR
SESSION RECONSTRUCTION
141378
‫שיטה והתקן לשיחזור זמן עבודה עם‬
‫מחשב‬
]22[
]31[
26.06.2000
60/141351
]32[ 28.06.1999
]33[ US
09/552818
20.04.2000
US
09/553261
20.04.2000
US
]51[ Int. Cl.8 G06F 019/00, H04L 012/14, 012/26, H04Q 011/00
]71[ XACCT TECHNOLOGIES, INC.,
U.S.A.
]87[ WO/2001/001726
]74[ WOLFF, BREGMAN AND GOLLER,
,‫ ברגמן וגולר‬,‫וולף‬
19B KEREN HAYESOD ST.
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
P.O.B. 1352,
JERUSALEM 91013
[57] A system for reconstructing a
source, the packet source generating a
session, the system comprising: a packet
plurality of packets; a flow manager
1135
July 5, 2006– ‫ט' בתמוז התשס"ו‬
coupled to the packet source, the flow
manager identifying at least one flow in
the plurality of packets; an application
recognizer coupled to the flow manager,
the application recognizer identifying an
application corresponding to the at least
one flow; a session streamer coupled to the
flow manager, the session streamer
identifying a plurality of flows in the
plurality of packets corresponding to the
session based on the application.
__________
]11[]21[
July 5, 2006– ‫ט' בתמוז התשס"ו‬
141414
1136
‫שימוש בבנזנסולפוניל(תיאו) אוריאות‬
‫להכנת תרופה לטיפול בחוסר פעילות של‬
,‫מערכת העצבים האוטונומית ולמניעתה‬
‫השמוש שלהם עם חוסמי רצפטור – בטא‬
‫וכמה בנזנסולפוניל (תיאו) אוריות חדשות‬
]54[
USE OF BENZENESULFONYL
(THIO) UREAS FOR PREPARING
A MEDICAMENT FOR THE
TREATMENT AND
PROPHYLAXIS OF
DYSFUNCTIONS OF THE
AUTONOMOUS NERVOUS
SYSTEM, THEIR USE WITH BETA
- RECEPTOR BLOCKERS, AND
SOME SUCH NOVEL
BENZENESULFONYL (THIO)
UREAS
]22[
]31[
02.09.1999
19841534.6
]32[ 10.09.1998
]33[ DE
19901061.7
14.01.1999
DE
Int. Cl.8 A61K 031/18, 031/64, A61P 003/10, 009/06, C07C 311/57, 323/67, 335/42
AVENTIS PHARMA
DEUTSCHLAND GMBH, GERMANY
WO/2000/015204
PEARL COHEN ZEDEK LATZER,
‫ עורכי פטנטים‬,‫פרל כהן צדק לצר עורכי דין‬
5 SHENKAR STREET,
,‫ונוטריונים‬
P.O.BOX 12704
‫ הרצליה‬,12704 .‫ד‬.‫ ת‬, 5‫שנקר‬
HERZLIYA 46733
]51[
]71[
]87[
]74[
[57] The use of a benzenesulfonyl (thio)
urea of the formula
in which
R1 is hydrogen, methyl or trifluoromethyl;
R2 is hydrogen, halogen, (C1-C6)-alkyl,
(C1-C6)-alkoxy, (C1-C6)-alkoxy-(C1-C4)alkoxy-, (C1-C6)-alkoxy-(C1-C4)-alkoxy(C1-C4)-alkoxy-, (C1-C6)-alkylthio, (C1C6)-fluoroalkoxy or (C1-C6)-fluoroalkyl;
E is oxygen or sulfur;
Y is a hydrocarbon residue of the formula -(CR32)n--in which the residues R3
independently of one another are each
hydrogen or (C1-C2)-alkyl and n is 1, 2, 3
or 4;
1137
X is hydrogen, halogen or (C1-C6)-alkyl;
Z is halogen, nitro, (C1-C4)-alkoxy or (C1C4)-alkyl;
in any of its stereoisomeric forms and/or
mixture thereof in any ratio, and/or of a
physiologically acceptable salt thereof for
preparing a medicament for the treatment
or prophylaxsis of a dysfunction of the
autonomous nervous system. Claimed as
novel are the pharmaceutical preparation,
comprising one or more compounds of the
the formula I in any of their stereoisomeric
forms or mixtures thereof in any ratios,
July 5, 2006– ‫ט' בתמוז התשס"ו‬
and/or their physiologically acceptable
salts, one or more beta-receptor blockers
and/or their physiologically acceptable
salts and a physiologically acceptable
carrier and the new compounds selected
from 1-[[5-[2-)5-tert-Butyl-2methoxybenzamido) ethyl]-2methoxyphenyl]sulfonyl]-3methylthiourea, 1-[[5-(5-tert-Butyl-2methoxybenzamido) ethyl]-2methoxyphenyl] sulfonyl]-3-methylurea,
1-[[5-[2-(5-isopropyl-2methoxybenzamido) ethyl]-2methoxyphenyl] sulfonyl]-3methylthourea,
1-[[5-[2-(5-tert-Butyl-2methoxybenzmido) ethyl]-2-(2methoxyethoxy) phenyl] sulfonyl]-3methylthiourea, their physiologically
acceptable salts and 1-[[5-[2-(5-tert-Butyl2-methoxybenzamido) ethyl]-2methoxyphenyl]sulfonyl]-3-methylthourea
sodium salt.
__________
]11[]21[
]54[
IMMEDIATE RELEASE TABLET
]22[
]31[
]51[
]71[
]72[
27.08.1999
9802973-9
]32[ 03.09.1998
Int. Cl.8 A61K 009/00, A61P 007/02
ASTRAZENECA AB, SWEDEN
FORSMAN SIGBRIT, KARLSSON
CHRISTER, KARLSSON MAGNUS
WO/2000/013671
LUZZATTO & LUZZATTO,
P.O.B 5352
BEER-SHEVA 84965
]87[
]74[
[57] An oral immediate release
formulation in solid form, comprising (a) a
low molecular weight peptide thrombin
inhibitor having pH dependent solubility
and having a particle size of less than
The applications for division
from this application have
not yet been published
141439
‫טבלית בעלת שחרור מידי‬
]33[
SE
,‫לוצאטו את לוצאטו‬
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשיה‬
300µm, and (b) a combination of
microcrystalline cellulose and sodium
starch glycollate in an amount higher than
35% w/w of the formulation.
,171593
‫בקשות חלוקה מבקשה זו‬
.‫שטרם פורסמו‬
_________
]11[]21[
July 5, 2006– ‫ט' בתמוז התשס"ו‬
141462
1138
]54[
INSERTABLE STENT AND
METHODS OF MAKING AND
USING THE SAME
]22[
]31[
]51[
]71[
18.08.1999
60/097357
]32[ 21.08.1998
Int. Cl.8 A61F 002/06
PROVIDENCE HEALTH SYSTEM OREGON, U.S.A.
WO/2000/010488
SANFORD T.COLB & CO.,
P.O.B. 2273,
REHOVOT
]87[
]74[
[57] An insertable stent (12) for joining
together and facilitating healing of
adjacent tissues, the tissues (18, 20)
defining an internal cavity, the insertable
stent comprising an insertable stent body
including at least one fusible portion (24),
and at least one unfusible portion having a
‫סטנט להחדרה ושיטות לייצורו ושימושו‬
]33[
US
,,'‫ קולב ושות‬.‫סנפורד ט‬
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
portion which is dissolvable during healing
permitting fluid to pass therethrough, the
insertable stent body being introduceable
into, and fitting within the confines of the
internal cavity, in contact with and fusible
to the adjacent tissues.
__________
]11[]21[
1139
141596
July 5, 2006– ‫ט' בתמוז התשס"ו‬
‫תרכובות אזה–דוציקליים המווסתים עיכוב‬
‫ תכשירים פרמצבטיים‬,‫הצמדת תאים‬
‫המכילים אותן וכמה תרכובות כאלה‬
]54[
AZA-BICYCLIC COMPOUNDS
WHICH MODULATE THE
INHIBITION OF CELL
ADHESION, PHARMACEUTICAL
COMPOSITIONS CONTAINING
THEM AND SOME SUCH NOVEL
COMPOUNDS
]22[
]31[
26.08.1999
9818641.4
]32[ 26.08.1998
]33[ GB
60/110008
25.11.1998
US
Int. Cl.8 A61K 031/395, A61P 011/06, 029/00, 043/00, C07D 209/08, 209/10,
209/30, 215/04, 215/12, 215/16, 223/16, 401/12, 403/12, 405/12, 409/12, 413/12,
417/12
AVENTIS PHARMA LIMITED,
UNITED KINGDOM
WO/2000/015612
SANFORD T.COLB & CO.,
,,'‫ קולב ושות‬.‫סנפורד ט‬
P.O.B. 2273,
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
REHOVOT
]51[
]71[
]87[
]74[
[57] Compounds of the formula
wherein;
R1 represents R3-L3-Ar1-L4-Z3-;
R2 represents hydrogen, halogen, C1-4 alkyl
or C1-4 alkoxy; R3 represents alkyl, alkenyl,
alkynyl, aryl, arylalkyl, arylalkenyl,
arylalkynyl, cycloalkyl, cycloalkylalkyl,
cycloalkylalkenyl, cycloalkenyl,
cycloalkenylalkyl, heteroaryl,
heteroarylalkyl, heteroarylalkenyl,
heteroarylalkynyl, heterocycloalkyl or
heterocycloalkylalkyl;
R5 represents hydrogen or C1-4 alkyl; R7
and R7a are each independently hydrogen
or C1-4 alkyl; R8 represents hydrogen,
alkyl, aryl, arylalkyl, cycloalkyl,
cycloalkylalkyl, heteroaryl,
July 5, 2006– ‫ט' בתמוז התשס"ו‬
heteroarylalkyl, heterocycloalkyl or
heterocycloalkylalkyl;
R9 represents alkyl, aryl, cycloalkyl,
heteroaryl or heterocycloalkyl, heteroaryl
or heterocycloalkyl, or alkyl substituted by
aryl, carboxy, cycloalkyl, heteroaryl,
heterocycloallyl, -S(O)mR3, -C(=O)-NY4Y5
or –NY4Y5;
R10 represents hydrogen, R3 or alkyl
substituted with alkoxy, cycloalkyl,
hydroxy, mercapto, alkylthio or –NY4Y5;
R14 represents alkyl, aryl, arylalkyl,
cycloalkyl, cycloalkylalkyl, heteroaryl,
hetetoarylalkyl, heterocycloalkyl or
heterocycloalkylalkyl;
1140
A1 represents a methylene or ethylene
linkage;
Ar1 represents arylene;
L1 represents:
an allylene linkage optionally substituted
by (a) carboxy, hydroxy, mercapto, R3, N(R8)-C(=O)-R9, -N(R8)-C(=O)-OR9, N(R8)- SO2-R9 or –NY4Y5, or by (b) alkyl
substituted by carboxy, hydroxy, mercapto,
S(O)mR9, -C(=O)- NY4Y5 or –NY4Y5;
L3 represents an –NR5-C(=Z)-NR5 –
linkage;
L4 represents an alkylene chain;
Y1 and Y2 are independently hydrogen,
alkenyl, alkyl, aryl, arylalkyl, cycloalkyl,
heteroaryl or heteroarylalkyl; or the group
–NY1Y2 may form a cyclic amine; Y4 and
Y5 are independently hydrogen, alkenyl,
alkyl, alkynyl, aryl, cycloalkenyl,
cycloalkyl, heteroaryl, heterocycloalkyl, or
alkyl substituted by alkoxy, aryl, cyano,
cycloalkyl, heteroaryl, heterocycloalkyl,
hydroxy, oxo, -NY1Y2, or one or more –
CO2 R8 or –C(=O)-NY1Y2 groups; or the
group –NY4Y5 may form a 5- to 7membered cyclic amine which (i) may be
optionally substituted with one or more
substituents selected from alkoxy,
carboxamido, carboxy, hydroxy, oxo, or a
5-, 6- or 7-membered cyclic acetal
derivative thereof, or R10; (ii) may also
contain a further heteroatom selected from
O, S, SO2, or NY6; and (iii) may also be
fused to additional aryl, heteroaryl, heterocycloalkyl or cycloalkyl rings to form a
bicyclic or tricyclic ring system; Y6
represents hydrogen, alkyl, aryl, arylalkyl,
-C(=O)-R14, -C(=O)OR14 or SO2R14;
Z is an oxygen or sulphur atom;
Z1 is C(R7)(R7a);
Z3 is C(=O) or OC(=O);
m is an integer 1 or 2; and
Y is carboxy;
and their ester prodrugs; and
pharmaceutically acceptable salts and
solvated of such compounds and their ester
prodrugs.
__________
]11[]21[
]54[
HYDROGEL COMPOSITIONS
FOR THE CONTROLLED
RELEASE ADMINISTRATION OF
GROWTH FACTORS
]22[
]31[
]51[
]71[
]87[
]74[
03.09.1999
60/099168
]32[ 04.09.1998
Int. Cl.8 A61K 047/10, 047/32, 047/36
SCIOS INC., U.S.A.
WO/2000/013710
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.BOX 4060,
TEL AVIV 61040
[57] A hydrogel composition for the
controlled release delivery of a polypeptide
1141
141688
‫תכשירי הדרוג'ל למתן בשחרור מבוקר‬
‫של גורמי גידול‬
]33[
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
growth factor comprising:
(a) a therapeutically effective amount of a
polypeptide growth factor containing at
least one region of positive charge;
July 5, 2006– ‫ט' בתמוז התשס"ו‬
(b) a physiological acceptable watermiscible anionic polymer;
(c) a physiologically acceptable watermiscible non-ionic polymeric viscosity
controlling agent; and
(d) water.
__________
]11[]21[
]54[
BUCK-BOOST POWER
CONVERTER AND TWO-LEVEL
INPUT MULTIPLE OUTPUT
SWITCHING POWER SUPPLY
BASED ON THE CONVERTER
]22[
]51[
]71[
]74[
01.03.2001
Int. Cl.8 H02M 003/335
ALVARION ISRAEL (2003) LTD
ECI TELECOM LTD,
30 HASIVIM ST.
PETACH TIKVA 49517
[57] A buck-boost power converter
capable of converting a high voltage input
(12) and a low voltage input (32) into an
intermediate voltage to be obtained
between a first, negative, and a second,
positive, intermediate voltage contacts, the
converter comprising a buck converter
integrally interconnected with a boost
converter, wherein: said buck converter
comprises components including a
transistor switch (Q1), a diode (18), an
inductance coil (20), a capacitor (22) and a
control circuit (24), wherein the transistor
switch is controlled via its gate by the
control circuit, its source being connected
to a common of said input voltages, its
July 5, 2006– ‫ט' בתמוז התשס"ו‬
141741
‫ וספק כח‬,BUCK–BOOST ‫ממיר כח‬
,‫למיתוג בעל שתי כניסות ומספר יציאות‬
‫המבוסס על ממיר זה‬
‫ תל אביב‬,‫) בע"מ‬2003( ‫אלווריון ישראל‬
,‫ טלקום בע"מ‬.‫ איי‬.‫ סי‬.‫אי‬
‫ פתח תקוה‬,30‫רחוב הסיבים‬
drain is connected to the high input voltage
via the diode, and also coupled to a first
end of the inductance coil which at its
second end is connected to the negative
intermediate voltage contact; the positive
intermediate voltage contact being
connected to the high voltage input, and
the capacitor is connected between said
first and second intermediate voltage
contacts;
said boost converter utilizing said
components and the structure of the buck
converter, and further comprising
connection of the low input voltage to the
second end of said inductance coil.
1142
__________
]11[]21[
]54[
DEVICE FOR SCANNING AN
INFORMATION CARRIER,
METHOD OF MANUFACTURING,
AND INFORMATION CARRIER
]22[
]31[
]51[
]71[
05.07.2000
99202286.3
]32[ 13.07.1999
Int. Cl.8 G11B 020/18
KONINKLIJKE PHILIPS
ELECTRONICS N.V., THE
NETHERLANDS
WO/2001/004895
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.BOX 4060,
TEL AVIV 61040
]87[
]74[
[57] A device for scanning an
information carrier (1), which information
carrier carries identification information
(10, 11) and user information the
identification information being spread
over the information carrier and the
information including data (7, 13) and
parities (8, 12), which device includes read
means (42, 34) for reading the information
present on the information carrier, the
1143
141932
‫ שיטת ייצור‬,‫התקן הסורק נשא מידע‬
‫ונשא מידע‬
]33[
EP
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
device including an error correction means
(45) for the correction of errors in both the
identification information and the user
information, the device further including
organization means (46) for the
organization of the information in such a
manner that both the identification
information and the user information are
processed by the error correction means.
July 5, 2006– ‫ט' בתמוז התשס"ו‬
__________
]11[]21[
]54[
USE OF ATORVASTATIN FOR
PREPARATION OF A
MEDICAMENT FOR
PREVENTING OR DELAYING
CATHETER-BASED
REVASCULARIZATION
]22[
]31[
]51[
]71[
08.07.1999
60/102457
]32[ 30.09.1998
Int. Cl.8 A61K 045/00, C07D 207/416
WARNER-LAMBERT COMPANY
LLC, U.S.A.
WO/2000/018395
LUZZATTO & LUZZATTO,
P.O.B 5352
BEER-SHEVA 84965
]87[
]74[
[57] Use of atorvastin or a
pharmaceutically acceptable salt thereof in
an amount effective to cause an aggressive
lowering of LDL cholesterol by at least
forty percent from baseline, in the
141953
‫שימוש של אטורוסטטין להכנת תרופה‬
‫למניעה או דחייה של רבסקולריזציה‬
‫המבוססת על קטטר‬
]33[
US
,‫לוצאטו את לוצאטו‬
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשיה‬
preparation of a medicament for
preventing or delaying catheter-based
revascularization in patients suffering from
coronary artery disease in need of such
treatment.
__________
July 5, 2006– ‫ט' בתמוז התשס"ו‬
1144
]11[]21[
]54[
THERMAL CONDITIONING
APPARATUS
]22[
]31[
]51[
]71[
07.10.1999
09/167663
]32[ 07.10.1998
Int. Cl.8 A61F 007/00
RESPIRATORY SUPPORT
PRODUCTS INC., U.S.A.
WO/2000/019946
REINHOLD COHN AND PARTNERS,
P.O.BOX 4060
TEL AVIV 61040
]87[
]74[
[57] A thermal conditioning apparatus for
delivering a thermal medium to a patient
comprising: a first material layer (110)
having a substantially planar
configuration; a second material layer
(120) having a substantially planar
configuration, the first material layer
bonded to the second material layer at
portions thereof to define a pair of
extending portions that are spaced to
permit a patient to be positioned between
the extending portions and to provide an
inflatable medium delivery space (102)
therebetween; an inlet portion (150) in
connection with the medium delivery
142000
‫מכשיר למיזוג תרמי‬
]33[
US
,‫ריינהולד כהן ושותפיו‬
‫אביב‬-‫ תל‬,4060 .‫ד‬.‫ת‬
space to receive a thermally conditioned
medium; a plurality of orifices on the pair
of extending portions (165) to deliver the
thermally conditioned medium to the
patient; and a segmented cover portion
formed from the first and second material
layers to extend laterally outward from one
of the extending portions and of a length to
permit folding the segmented cover portion
over the patient folding the segmented
cover portion over the patient and the
respective pair of extending portions
whereby selective portions of the patient
may be exposed by opening a segment of
the segmented cover portion.
__________
1145
July 5, 2006– ‫ט' בתמוז התשס"ו‬
]11[]21[
142066
‫תולדות ארילסולפונאנאליד שתנן ותכשירי‬
‫רוקחות המכילים אותן‬
]54[
ARYLSULFONANILIDE UREA
DERIVATIVES AND
PHARMACEUTICAL
COMPOSITIONS CONTAINING
THE SAME
]22[
]31[
]51[
21.09.1999
60/100888
]32[ 23.09.1998
]33[ US
Int. Cl.8 A61K 031/18, 031/33, A61P 003/06, C07C 311/21, 323/39, 335/16, C07D
231/38, 233/54, 249/04, 257/06, 263/30, 277/48, 285/12, 295/20, 307/52
TULARIK INC., U.S.A.
WO/2000/017159
WOLFF, BREGMAN AND GOLLER,
,‫ ברגמן וגולר‬,‫וולף‬
19B KEREN HAYESOD ST.
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
P.O.B. 1352,
JERUSALEM 91013
]71[
]87[
]74[
[57] Compounds of the formula:
or pharmaceutically acceptable salts
thereof, wherein X is O, S or NH; R1 and
R2 are each independently hydrogen, a (C1C6) alkyl or a (C1-C6) heteroalkyl; R3 is
hydrogen, a (C1-C6) alkyl or a (C1-C6)
heteroalkyl, or is combined with Y and the
nitrogen atom to which each is attached to
form a 5-, 6- or 7-membered heterocyclic
ring; R4 is hydrogen, a halogen, a (C1-C8)
alkyl, a (C1-C8) heteroalkyl, -OR11, -SR11
or –NR11 R12, wherein R11 and R12 are each
July 5, 2006– ‫ט' בתמוז התשס"ו‬
independently hydrogen, a (C1-C8) alkyl or
a (C1-C8) heteroalkyl;
Y is hydrogen, a heterocyclic ring, a (C1C8) alkyl; a (C1-C8) heteroalkyl; an aryl; an
aryl (C1-C4) alkyl; an aryl (C1-C4)
heteroalkyl; a heteroaryl (C1-C4) alkyl or a
heteroaryl (C1-C4) heteroalkyl, or is
optionally linked together with R3 to form
a 5-, 6- or 7-membered heterocylic ring;
and Ar is a member selected from the
group consisting of:
1146
wherein
X1 and X2 are each independently F, Cl
and Br,
in which the term "alkyl", by itself or as
part of another substituent, means a
straight or branched chain, or cyclic
hydrocarbon radical, or combination
thereof, which may be fully saturated,
mono-or polyunsaturated and can include
di-or multi-radicals having the number of
carbon atoms designated; the term
"heteroalkyl", by itself or in combination
with another term, means, a stable straight
or branched chain, or cyclic hydrocarbon
radical, or combinations thereof, which
may be fully saturated, mono-or
polyunsaturated and can include di-and
multi-radicals, consisting of the stated
number of carbon atoms and from one to
three heteroatoms selected from the group
consisting of O, N, Si and S, and wherein
the nitrogen and sulfur atoms may
optionally be oxidized and the nitrogen
heteroatom may optionally be quaternized.
__________
]11[]21[
142094
‫שיטה לבקרת חלוקה והתקינות של‬
‫תאי נבט ומקור‬
]54[
METHODS OF CONTROLLING
PROLIFERATION OF STEM AND
PROGENITOR CELLS AND THEIR
USE
]22[
]31[
17.08.1999
161659
]32[ 29.09.1998
]33[ US
PCT/US99/02664
08.02.1999
WO
Int. Cl.8 A61K 035/12, A61P 043/00, C12N 005/06
HADASIT MEDICAL RESEARCH
‫הדסית שרותי מחקר רפואי ופתוח‬
SERVICES AND DEVELOPMENT LTD.
‫ ירושלים‬,‫בע"מ‬
GAMIDA-CELL LTD.
‫ ירושלים‬,‫סל בע"מ‬-‫גמידה‬
WO/2000/018885
G.E. EHRLICH (1995) LTD.,
,‫) בע"מ‬1995( ‫ארליך‬.‫אי‬.‫ג'י‬
AYALON TOWER 15TH FLOOR
‫ רחוב מנחם בגין‬15 ‫מגדל אילון קומה‬
11 MENACHEM BEGIN STREET
‫ רמת גן‬,11
52521 RAMAT GAN
]51[
]71[
]87[
]74[
[57] An assay for determining whether a
transition metal chelator which binds
copper causes inhibition or induction of
differentiation, the assay comprising the
step of culturing a population of stem or
progenitor cells or cells of a substantially
non-differentiated cell line, in the presence
of the transition metal chelator and
monitoring differentiation of said cells,
wherein if differentiation is increased as is
compared to non-treated cells, the
transition metal chelator induces
differentiation, whereas if differentiation is
decreased or as compared to non-treated
cells, or if differentiation is absent
altogether, the transition metal chelator
inhibits differentiation.
__________
1147
July 5, 2006– ‫ט' בתמוז התשס"ו‬
]11[]21[
]54[
SYSTEM FOR PERFORMING
MAINTENANCE TEST BETWEEN
LAN CONNECTING DEVICES
AND THE SAME LAN
CONNECTING DEVICE
]22[
]31[
]51[
]71[
29.09.2000
11-277002
]32[ 29.09.1999
Int. Cl.8 H04L 012/26, 012/46
HITACHI TELECOM
TECHNOLOGIES LTD., JAPAN
YOSHIDA TAKAHIRO, GOKAN
SHIN-ICHI, SATO TSUOYSHI
WO/2001/024449
SOROKER-AGMON,
14 SHENKAR STREET,
HERZLIYA PITUAH 46725
]72[
]87[
]74[
[57] A system for performing
maintenance test between LAN connecting
devices in which a plurality of LAN
connecting devices connectable to a LAN
are connected to each other through a
circuit using an optical fiber as a physical
medium, said system comprising a test
means which separates from each other the
input/output wavelength of a
communication means for performing an
142097
‫מערכת לביצוע בדיקות אחזקה בין התקני‬
‫קישור של מערכות תקשורת מקומיות‬
]33[
JP
,‫אגמון‬-‫סורוקר‬
‫ הרצליה פיתוח‬,14 ‫בית נולטון רחוב שנקר‬
ordinary LAN communication between
terminals of a physical communication or
between terminals of a logical
communication and the input/output
wavelength of a test communication means
for performing a test of communication,
and said system performing a maintenance
test on a path between said LAN
connecting devices.
__________
July 5, 2006– ‫ט' בתמוז התשס"ו‬
1148
]11[]21[
]54[
ENVIRONMENTALLY BENIGN
CROP PROTECTION AGENTS
]22[
]31[
]51[
]71[
]87[
]74[
23.09.1999
159814
]32[ 23.09.1998
Int. Cl.8 A01N 041/02
CERNO BIOSCIENCES LLC, U.S.A.
WO/2000/016632
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.BOX 4060,
TEL AVIV 61040
142131
‫גורמים לשמירת גידולים ידידותיים‬
‫לסביבה‬
]33[
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
[57] A plant cell surface comprising an
effective amount of bioavailable antifouling compound of the formula
wherein
X represents –OH, -O(aryl), -O(acyl), O(sulfonyl), -CN, F, Cl, or Br;
Y represents O, S, Se, or NR;
Z represents optionally substituted alkyl,
heteroalkyl, cycloalkyl, heterocycloalkyl,
aryl, heteroaryl, aralkyl, heteroaralkyl, or –
(CH2)m-R80;
R represents independently for each
occurrence hydrogen, alkyl, heteroalkyl,
aryl, heteroaryl, aralkyl, heteroaralkyl, or –
(CH2)m-R80;
R80 represents independently for each
occurrence aryl, cycloalkyl, cycloalkenyl,
heterocyclyl, or polycyclyl; and m is an
integer in the range 0 to 8 inclusive, or a
salt thereof, wherein the compound or a
biologically active fragment thereof can be
released from the surface in the presence
of a liquid or vapor; provided that when X
is –OH, and Y is O, Z is not an alkyl
group; and provided that when X is –OH,
and Y is O, Z is not 5-aceto-8-quinolinyl.
__________
1149
July 5, 2006– ‫ט' בתמוז התשס"ו‬
]11[]21[
]54[
PRODUCTS AND METHODS FOR
BRACHYTHERAPY
]22[
]31[
05.11.1999
60/107406
]32[ 06.11.1998
9826121.7
27.11.1998
Int. Cl.8 A61B 008/00
GE HEALTHCARE LIMITED,
UNITED KINGDOM
WO/2000/028554
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.BOX 4060,
TEL AVIV 61040
]51[
]71[
]87[
]74[
[57] A method of real-time visualisation
of a brachytherapy seed comprising:
(i) implanting a brachytherapy seed having
at least one part of a container surface
roughened, shaped or otherwise treated to
142166
‫תוצרים ושיטות לטיפול קרינתי מקומי‬
]33[
US
GB
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
impart improved ultrasound visibility in a
tissue or organ of interest;
(ii) imaging with ultrasound; and
(iii) recording the position of the implanted
brachytherapy seed.
__________
]11[]21[
]54[
PROCESS FOR THE
PREPARATION OF CORROLES
AND SEVERAL SUCH NEW
COMPOUNDS, INCLUDING
CHIRAL
DERIVATIVES, AND
THE USE THEREOF
]22[
]31[
]51[
]71[
15.09.1999
126426
]32[ 29.09.1998
Int. Cl.8 C07D 487/22
TECHNION RESEARCH AND
DEVELOPMENT FOUNDATION
LTD.
WO/2000/018771
REINHOLD COHN AND
PARTNERS,
21 AHAD HA'AM ST.,
P.O.BOX 4060,
TEL AVIV 61040
]87[
]74[
July 5, 2006– ‫ט' בתמוז התשס"ו‬
142192
‫תהליך להכנת קורולים ומספר קורולים‬
‫ כולל תולדות כירליות והשימוש‬,‫חדשים‬
‫בהם‬
]33[
IL
‫ חיפה‬,‫מוסד הטכניון למחקר ופיתוח בע"מ‬
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
1150
[57] A process for the preparation of a
compound or salts, optically active isomers
and complexes thereof of the formula
wherein:
each R1 is hydrogen or is selected from
straight or branched C1-C12 alkyl, aralkyl,
aryl, heteroaryl, R2 and R3 are identical or
different and each R2 and each R3
represents hydrogen or a radical selected
from straight or branched C1-C12 alkyl,
aralkyl, aryl, and R4, R5 and R6 are each
hydrogen or represent identical or different
radicals selected from straight or branched
C1-C12 alkyl, aralkyl, aryl, acyl,
alkylsulfonyl or arylsulfonyl; which
process comprises solvent-free
condensation of an aldehyde of formula II
with a pyrrole of formula III
wherein R1, R2 and R3 are as defined
above, followed by dehydrogenation, to
obtain a compound of formula I wherein
R4, R5 and R6 are hydrogen.
__________
]11[]21[
1151
142314
July 5, 2006– ‫ט' בתמוז התשס"ו‬
]54[
CHARACTERISING
POLYPEPTIDES THROUGH
CLEAVAGE AND MASS
SPECTROMETRY
]22[
]31[
]51[
]71[
01.10.1999
9821393.7
]32[ 01.10.1998
Int. Cl.8 G01N 033/68
XZILLION GMBH & CO. KG,
GERMANY
WO/2000/020870
EITAN, PEARL, LATZER AND
COHEN ZEDEK,
P.O.B. 12688,
HERZLIYA 46733
]87[
]74[
[57] A method for characterizing a
population of parent polypeptides in a
sample, which method comprises:
(a) contacting a first portion of the sample
with a first sequence-specific cleavage
agent to generate polypeptide fragments;
(b) isolating one or more polypeptide
fragments, each fragment comprising the
N-terminus or the C-terminus of the parent
polypeptide from which it was fragmented;
(c) identifying the isolated fragments by
mass spectrometry;
‫אפיון פוליפפטידים ע"י חיתוך‬
‫ספקטרומטרית מסה‬
]33[
GB
,‫ לצר וכהן צדק‬,‫ פרל‬,‫איתן‬
‫ הרצליה‬,12688 .‫ד‬.‫ ת‬, 7 ‫רחוב שנקר‬
(d) repeating steps (a)-(c) on a second
portion of the sample using a second
sequence-specific cleavage agent that
cleaves at a different site from the first
cleavage agent, wherein the second
cleavage agent is different from the first
cleavage agent, and wherein the second
portion of the sample is separate from the
first portion of the sample; and
(e) characterizing the parent polypeptides
in the sample from the fragments identified
in steps (c) and (d).
__________
]11[]21[
July 5, 2006– ‫ט' בתמוז התשס"ו‬
142483
1152
]54[
METHOD FOR CHECKING
TABLESPACES INVOLVED IN
REFERENTIAL INTEGRITY
]22[
]31[
27.10.1999
60/105883
]32[ 27.10.1998
09/208118
09.12.1998
Int. Cl.8 G06F 017/30
COMPUTER ASSOCIATES THINK,
INC., U.S.A.
WO/2000/025237
LUZZATTO & LUZZATTO,
P.O.B 5352
BEER-SHEVA 84965
]51[
]71[
]87[
]74[
[57] A method for checking tablespaces
in a database management system, the
database management system including a
load utility and a check utility, the method
comprising the steps of: parsing a load
utility control statement; determining, as a
function of the parsed load utility control
‫שיטה לבדיקת שלמות הנתונים במרחבים‬
‫טבלאיים‬
]33[
US
US
,‫לוצאטו את לוצאטו‬
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשיה‬
statement, if a check utility is identified; if
the check utility is identified, allocating a
persistent storage area for use by the load
utility; recording, by the load utility, a
name of a tablespace in the persistent
storage area; and locating the persistent
storage area for use by the check utility.
__________
]11[]21[
1153
142525
July 5, 2006– ‫ט' בתמוז התשס"ו‬
]54[
MEMBRANE OR MATRIX FOR
CONTROLLING DRUG
PERMEATION
]22[
]31[
]51[
]71[
]87[
]74[
26.10.1999
190608
]32[ 12.11.1998
Int. Cl.8 A61K 009/00
SCHERING OY, FINLAND
WO/2000/029464
SANFORD T.COLB & CO.,
P.O.B. 2273,
REHOVOT
[57] A method for controlling the
permeation of a drug over a prolonged
period of time by the use of siloxane-based
elastomer, comprising dispersing said drug
within said siloxane-based elastomer to
form a matrix or encasing said drug as a
core within a membrane comprising said
siloxane-based elastomer, wherein said
elastomer comprises 3, 3, 3, trifluoropropyl groups attached to the Siatoms of the siloxane units, wherein from
1 to approximately 50% of the substituents
attached to the Si-atoms in the siloxane
units are 3, 3, 3, -trifluoropropyl groups,
‫קרום או סריג לבקרת חלחול תרופות‬
]33[
US
,,'‫ קולב ושות‬.‫סנפורד ט‬
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
and wherein the elastomer is made of
either
(i) a mixture comprising (a) a nonfluorosubstituted siloxane-based polymer
and (b) a fluorosubstituted siloxane-based
polymer, said polymer comprising 3, 3, 3,trifluoropropyl groups attached to the Siatoms of the siloxane units, or
(ii) a single siloxane-based polymer
comprising 3, 3, 3, - trifluoropropyl groups
attached to the Si-atoms of the siloxane
units, wherein said polymer or mixture of
polymers are crosslinked to form the
elastomer.
__________
]11[]21[
July 5, 2006– ‫ט' בתמוז התשס"ו‬
142609
1154
–N,N) – 3 – ‫ – אמינו‬1 –‫שימוש ב‬
‫ – חומצה‬1,1 – ‫דימתילאמינו) – פרופילידן‬
‫ביספוספונית בתרופות להכנת תרופות‬
‫לעירור פעילויות תאיות של‬
‫אוסטאובלסטים‬
]54[
USES OF 1 - AMINO-3- (N,NDIMETHYLAMINO) PROPYLIDENE - 1,1 BISPHOSPHONIC ACID FOR
MANUFACTURING
MEDICAMENTS FOR
STIMULATING CELLULAR
ACTIVITIES OF OSTEOBLASTS
]22[
]31[
]51[
]71[
29.10.1999
P980105446
]32[ 30.10.1998
]33[ AR
Int. Cl.7 A61K 031/663, A61P 019/00, C07F 009/40
GADOR S.A., ARGENTINA
UNIVERSITY OF LEIDEN, THE
NETHERLANDS
WO/2000/025794
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.BOX 4060,
TEL AVIV 61040
]87[
]74[
[57] Use of 1-amino-3-(N,Ndimethylamino)-propylidene-1, 1bisphosphonic acid, any of its
pharmaceutical acceptable salts or any of
The applications for division
from this application have
not yet been published
its pharmaceutical acceptable hydrates for
the manufacture of a medicament for
stimulating cellular activites of osteoblasts.
,172603
‫בקשות חלוקה מבקשה זו‬
.‫שטרם פורסמו‬
__________
]11[]21[
1155
142675
July 5, 2006– ‫ט' בתמוז התשס"ו‬
]54[
PROGRAM PRODUCT AND DATA
PROCESSING SYSTEM
]22[
]31[
]51[
]71[
30.08.2000
11/244137
]32[ 30.08.1999
Int. Cl.8 G06F 009/30, 009/38
IP FLEX INC., JAPAN
TOMOYOSHI SATO, JAPAN
]72[
]87[
]74[
TOMOYOSHI SATO
WO/2001/016711
EITAN, PEARL, LATZER AND
COHEN ZEDEK,
P.O.B. 12688,
HERZLIYA 46733
[57] A data processing system,
comprising:
a plurality of processing units including
changeable input and/or output interfaces;
a unit for fetching a data flow designation
instruction for designating the input and/or
output interfaces of at least one of the
processing units independently of timing
‫תוצר תכנית ומערכת לעיבוד מידע‬
]33[
JP
,‫ לצר וכהן צדק‬,‫ פרל‬,‫איתן‬
‫ הרצליה‬,12688 .‫ד‬.‫ ת‬, 7 ‫רחוב שנקר‬
of execution of the processing unit; and a
data flow designation unit for decoding the
data flow designation instruction and
setting the input and/or output interfaces of
the processing unit for configuring a data
path from a plurality of the processing
units.
_________
]11[]21[
July 5, 2006– ‫ט' בתמוז התשס"ו‬
142702
1156
]54[
ANTIVIRAL FORMULATIONS
COMPRISING PROPYLENE
GLYCOL AND AN ISOPROPYL
ALKANOIC ACID ESTER
]22[
]31[
]51[
]71[
]87[
]74[
12.11.1999
9803929-0
]32[ 18.11.1998
Int. Cl.8 A61K 047/44
MEDIVIR AB, SWEDEN
WO/2000/029027
LUZZATTO & LUZZATTO,
P.O.B 5352
BEER-SHEVA 84965
[57] A topical composition in the form of
an oil water emulsion comprising 0.1-10%
(w/w) of an antiviral nucleoside analogue
selected from acyclovir, penciclovir or 9(4-hydroxy-2- (hydroxymethyl) butyl)
guanine in a pharmaceutical carrier
comprising propylene glycol and an
‫פורמולציות אנטיויראליות המורכבות‬
‫מפרופילן גליקול ואסטר של חומצת‬
‫איזופרופיל אלקנואית‬
]33[
SE
,‫לוצאטו את לוצאטו‬
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשיה‬
isopropyl C12-C22 alkanoic acid ester,
characterized in that the carrier comprises,
relative to the total weight of the
composition, 15-25% (w/w) propylene
glycol and 10-25% (w/w) of an isopropyl
C12-C22 alkanoic acid ester.
__________
]11[]21[
]54[
METHODS AND COMPOSITIONS
FOR THE PREVENTION OF
TOLERANCE TO MEDICATIONS
]22[
]31[
13.10.1999
60/106507
]32[ 30.10.1998
362540
28.07.1999
Int. Cl.8 A61K 045/00, 045/06
BAKER NORTON
PHARMACEUTICALS, INC., U.S.A.
WO/2000/025723
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.BOX 4060,
TEL AVIV 61040
]51[
]71[
]87[
]74[
[57] Use of therapeutically effective
amounts of a bronchodilator and of a
sulfated polysaccharide, wherein the
sulfated polysaccharide is a low-molecular
weight heparin (LMWH) or an ultra-low
1157
142865
‫שיטות ותכשירים למניעת עמידות‬
‫לתרופות‬
]33[
US
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
molecular weight heparin (ULMWH) for
the preparation of a pharmaceutical
composition for preventing tolerance to a
bronchodilator in a mammal.
July 5, 2006– ‫ט' בתמוז התשס"ו‬
__________
]11[]21[
142878
‫אביזרים בעלי משטחים בסגנון גרניט‬
]54[
FITTINGS HAVING GRANITE
STYLE SURFACES
]22[
]31[
]51[
]71[
16.11.1999
19853109.5
]32[ 18.11.1998
]33[ DE
Int. Cl.8 A47L 001/00, B29C 067/24, B44F 009/04
BLANCO GMBH ANDCO. KG,
GERMANY
WO/2000/028872
LUZZATTO & LUZZATTO,
,‫לוצאטו את לוצאטו‬
P.O.B 5352
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשיה‬
BEER-SHEVA 84965
]87[
]74[
[57] Fittings having a granite style
surface that are manufactured using
curable casting compounds of synthetic
materials which comprise a particulate
mineral filler, wherein the particle size lies
in the range of 0.1 to 2 mm and the
quantity thereof comprises 50 to 85 m%,
as well as a rheolgically effective additive
which is selected from modified
polycarbamides so that sinkage of the filler
during the casting and curing processes is
substantially avoided but the viscosity of
the casting compound containing the
additive nevertheless amounts to 6.3 Pa · s
or less.
__________
]11[]21[
July 5, 2006– ‫ט' בתמוז התשס"ו‬
142914
1158
]54[
SERUM FREE MEDIUM FOR
CHONDROCYTE-LIKE CELLS
]22[
]31[
]51[
]71[
08.11.1999
60/107646
]32[ 09.11.1998
Int. Cl.8 C12N 005/00, 005/06
ISTITUTO NAZIONALE PER LA
RICERCA SUL CANCRO, ITALY
CONSORZIO PER LA GESTIONE
DEL CENTRO DI BIOTECNOLOGIE
AVANZATE, ITALY
WO/2000/027996
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.BOX 4060,
TEL AVIV 61040
]87[
]74[
[57] A serum-free composition for the
culture of chondrocytes, comprising FGF2, linoleic acid, ascorbic acid, β-
‫תווך נטול נסיוב עבור תאים דמויי‬
‫כונדרוציטים‬
]33[
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
mercaptoethanol, transferrin and
dexamethasone.
__________
]11[]21[
]54[
METHOD AND APPARATUS FOR
INTERFACING WITH
INTELLIGENT THREEDIMENSIONAL COMPONENTS
]22[
]31[
]51[
]71[
03.11.1999
09/187284
]32[ 05.11.1998
Int. Cl.8 G06T 015/00
COMPUTER ASSOCIATES THINK,
INC., U.S.A.
WO/2000/028478
LUZZATTO & LUZZATTO,
P.O.B 5352
BEER-SHEVA 84965
]87[
]74[
[57] A method of interfacing with a threedimensional object that is displayed, said
method comprising the steps of: defining
said three-dimensional object as a
component with a component interface,
said component intrinsically containing an
intelligent content; displaying said
component interface; and interfacing
1159
142953
-‫שיטה ומיתקן לממשק עבור רכיבים תלת‬
‫מימדיים אינטליגנטיים‬
]33[
US
,‫לוצאטו את לוצאטו‬
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשיה‬
with said three-dimensional object through
said component interface. Said defining
step further comprises the steps of:
defining said component in a threedimensional content language; defining an
at least one property to describe said
component; and defining an at least one
route to interface said component with a
July 5, 2006– ‫ט' בתמוז התשס"ו‬
second component, so that said at least one
property and said at least one route
comprise a portion of said intelligent
content.
__________
]11[]21[
]54[
OSS SIGNATURE SCHEME
]22[
]51[
]71[
]72[
]74[
03.05.2001
Int. Cl.8 H04L 009/30
NDS LIMITED, UNITED KINGDOM
YAACOV (JORDAN) LEVY
SANFORD T.COLB & CO.,
P.O.B. 2273,
REHOVOT
[57] A method for digitally signing a
message, the method comprising:
providing a message digest (Mx, Mz):
providing a modulus N; providing a
number V in the ring ZN, wherein for
July 5, 2006– ‫ט' בתמוז התשס"ו‬
142962
OSS ‫תוכנית חתימת‬
‫יעקב (ירדן) לוי‬
,,'‫ קולב ושות‬.‫סנפורד ט‬
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
another number S in the ring ZN, V.S2=1 in
ZN; solving the equation (Mx + x)2 – V.y2 =
4.(Mz+z) in ZN to produce x, y, and z; and
assigning SIG as the signature of (Mx,
Mz), wherein SIG comprises (x, y).
1160
__________
]11[]21[
142983
– ß – L ‫תולדות‬
– 5 – ‫' – דידאוקסי‬3 ,'2 – ‫') – אזידו‬3 ‫' או‬2(
‫פלואורוציטוסין בעלי פעילות נוגדת וירוס‬
‫צהבת ותכשירי רוקחות המכילים אותן‬
]54[
ß - L - (2' OR 3') - AZIDO - 2', 3' DIDEOXY - 5 FLUOROCYTOSINE
DERIVATIVES WITH ANTI HEPATITIS B VIRUS ACTIVITY
AND PHARMACEUTICAL
COMPOSITIONS CONTAINING
THEM
]22[
]31[
05.11.1999
60/107116
]32[ 05.11.1998
]33[ US
60/115653
13.01.1999
US
Int. Cl.8 A61K 031/7068, A61P 031/12, C07H 019/06
EMORY UNIVERSITY, U.S.A.
CENTRE NATIONAL DE LA
RECHERCHE SCIENTIFIQUE
(C.N.R.S), FRANCE
THE UAB RESEARCH
FOUNDATION, U.S.A.
WO/2000/026225
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.BOX 4060,
TEL AVIV 61040
]51[
]71[
]87[
]74[
[57] Use of an effective amount of a β-L(2'-azido)-2'3',-dideoxy-5-fluorocytidine of
the formula:
1161
July 5, 2006– ‫ט' בתמוז התשס"ו‬
or a pharmaceutically acceptable ester, salt
or prodrug thereof, wherein R is H, acyl,
monophosphate, diphosphate, or
triphosphate, or a stabilizer phosphate
derivative (to form a stabilizied nucleotide
prodrug), and R' is H, acyl, or alkyl, for the
preparation of a medicament for the
treatment of hepatitis B virus infection in a
host.
__________
]11[]21[
143091
‫ תכשירי‬,N– ‫–ציאנופירולידינים מותמרים ב‬2
‫רוקחות המכילים אותם ושימושם בהכת‬
‫תרופה לטיפול במקרים הקשורים למניעת‬
DPP–IV
]54[
N-SUBSTITUTED 2CYANOPYRROLIDINES,
PHARMACEUTICAL
COMPOSITIONS COMPRISING
THEM AND USE THEREOF IN
THE PREPARATION OF
MEDICAMENTS FOR TREATING
CONDITIONS MEDIATED BY
DPP-IV INHIBITION
]22[
]31[
]51[
]71[
]87[
]74[
09.12.1999
09/209068
]32[ 10.12.1998
]33[ US
Int. Cl.8 A61K 031/40, A61P 003/10, C07D 207/16
NOVARTIS AG, SWITZERLAND
WO/2000/034241
LUZZATTO & LUZZATTO,
,‫לוצאטו את לוצאטו‬
P.O.B 5352
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשיה‬
BEER-SHEVA 84965
[57] A compound of the formula
July 5, 2006– ‫ט' בתמוז התשס"ו‬
1162
wherein R' represents hydroxy, C1-C7
alkoxy, C1-C8-alkanoyloxy, or R5R4N-COO-, where R4 and R5 independently are C1C7 alkyl or phenyl which is unsubstituted
or substituted by a substituent selected
from C1-C7 alkyl, C1-C7 alkoxy, halogen
and trifluoromethyl and where R4
additionally is hydrogen; or R4 and R5
together represent C3-C6 alkylene; and R"
represents hydrogen; or R' and R"
independently represent C1-C7 alkyl; in
free form or in form of a pharmaceutically
acceptable acid addition salt.
__________
]11[]21[
]54[
WIRELESS USER POSITION
UPDATE USING
INFRASTRUCTURE
MEASUREMENTS
]22[
]31[
]51[
]71[
18.11.1999
09/196448
]32[ 19.11.1998
Int. Cl.8 G01S 005/14
QUALCOMM INCORPORATED,
U.S.A.
WO/2000/029868
SANFORD T.COLB & CO.,
P.O.B. 2273,
REHOVOT
]87[
]74[
[57] A method for tracking a position of a
mobile unit in a mobile radio
communication system using information
from earth-orbiting satellites and
information received from infrastructure of
the system, wherein the infrastructure
consists of equipment associated with
transmitting and receiving voice or data
traffic to and from the mobile phone,
comprising the steps of:
(A) calculating an initial position of the
mobile unit using measurements from the
earth-orbiting satellites;
(B) calculating first and second range
measurements using first and second
signals transmitted between the mobile
unit and the infrastructure;
1163
143237
‫עדכון אל–חוטי של מיקום משתמש המנצל‬
‫מדידות תשתית‬
]33[
US
,,'‫ קולב ושות‬.‫סנפורד ט‬
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
(C) estimating a positional difference
between the initial position and a current
position of the mobile station with the first
and second range measurements, wherein
only range measurements made from
signals transmitted between the mobile
unit and infrastructure are used to perform
the estimating;
(D) determining an accuracy value
associated with the positional difference
estimated in step (C), and comparing the
accuracy value to a first threshold to
determine whether the positional
difference estimated in step (C) has an
acceptable accuracy;
(E) if the positional difference estimated in
step (C) has an acceptable accuracy, then
July 5, 2006– ‫ט' בתמוז התשס"ו‬
updating the initial position using the
positional difference and repeating steps
(B) – (D); and
(F) if the positional difference estimated in
step (C) does not have an acceptable
accuracy, then repeating steps (A) – (D).
__________
]11[]21[
]54[
OPTICAL ADD AND DROP
MULTIPLEXER
]22[
]51[
]71[
]74[
24.05.2001
Int. Cl.8 H04J 014/02
ECI TELECOM LTD.
ECI TELECOM LTD,
30 HASIVIM ST.
PETACH TIKVA 49517
143368
‫מרבב המעלה ומוריד אותות אופטיים‬
‫ פתח תקוה‬,‫ טלקום בע"מ‬.‫איי‬.‫סי‬.‫אי‬
,‫ טלקום בע"מ‬.‫ איי‬.‫ סי‬.‫אי‬
‫ פתח תקוה‬,30‫רחוב הסיבים‬
[57] A grouped optical add drop
multiplexer (GOADM) comprising: a
tunable periodic filter for dropping or
adding a group of optical wavelengths
from/to a spectrum of optical wavelengths
transmitted over an optical line so that
adjacent optical wavelengths in the
spectrum are initially spaced from one
another by a basic wavelength step "s",
wherein said tunable periodic filter is
inserted in said optical line as a primary
filter and is constructed to pick selected
wavelengths of the group such that
adjacent wavelengths of the group are
spaced from one another by a group step
being equal to ks, wherein k is an integer >
1; and at least one secondary filter
connected to said tunable periodic filter
serving as a primary filter, said at least one
secondary filter being automatically
tunable in response to tuning of said
tunable periodic filter.
__________
July 5, 2006– ‫ט' בתמוז התשס"ו‬
1164
]11[]21[
143390
) S ( ‫נוגד של קולטן ויטרונקטין חומצה‬
–8,7,6,5(–2[–3–‫ –דיהידרו‬11,10 –
–1–)‫–יל‬2–‫– נפתירידין‬8,1–‫טטרהידרו‬
–‫ ] ציקלוהפטן‬d,a [ ‫ – דיבנזו‬H5– ]‫אתוקסי‬
‫ תכשירי רוקחות‬,‫ הכנתו‬,‫–אצטית‬10
‫המכילים אותו ופריקרסר אלקיל אסטר‬
‫שלו‬
]54[
VITRONECTIN RECEPTOR
ANTAGONIST (S)-10,11-DIHYDRO3-[2-(5,6,7,8-TETRAHYDRO-1,8NAPHTHYRIDIN-2-YL)-1ETHOXY]-5HDIBENZO[A,D]CYCLOHEPTENE10-ACETIC ACID, ITS
PREPARATION,
PHARMACEUTICAL
COMPOSITIONS CONTAINING IT
AND ITS ALKYL ESTER
PRECURSOR
]22[
]31[
]51[
]71[
03.12.1999
60/110903
]32[ 04.12.1998
]33[ US
Int. Cl.8 A61K 031/4375, A61P 009/00, 019/08, 029/00, C07D 471/04
SMITHKLINE BEECHAM
CORPORATION, U.S.A.
WO/2000/033838
LUZZATTO & LUZZATTO,
,‫לוצאטו את לוצאטו‬
P.O.B 5352
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשיה‬
BEER-SHEVA 84965
]87[
]74[
[57] A compound of the formula
or a pharmaceutically acceptable salt thereof.
__________
]11[]21[
1165
143448
July 5, 2006– ‫ט' בתמוז התשס"ו‬
‫תכשיר קוטל פטריות‬
]54[
FUNGICIDE MIXTURE
]22[
]31[
]51[
]71[
11.12.1999
19859250.7
]32[ 22.12.1998
]33[ DE
Int. Cl.8 A01N 043/42, 047/24, C07D 215/16, 231/14, 249/10
BASF AKTIENGESELLSCHAFT,
GERMANY
WO/2000/036921
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.BOX 4060,
TEL AVIV 61040
]87[
]74[
[57] A fungicidal mixture, comprising as
active components
(a) a compound of the formula
its N-oxide or one of its salts where:
R1, R2, R3, R4 independently of one
another are: hydrogen, hydroxyl nitro,
halogen, C1-C4-alkyl, C1-C4 – haloalkyl,
C1-C4 – alkoxy, C1-C4 – haloalkoxy, C1-C4
– alkylthio, C1-C4 – haloalkylthio;
R5, R6, R7 independently of one another
are: hydrogen, hydroxyl, cyano, nitro,
halogen, C1-C7 – alkyl, C1-C7 – haloalkyl,
C1-C7 – alkoxy, C1-C7 – haloalkoxy, C1-C7
– alkylthio, C1-C7 – haloalkylthio, C1-C7 –
hydroxyalkyl, C2-C4 – acyl, aryl, aryloxy,
where the radicals with aryl may for their
part carry one to three of the following
groups: cyano, nitro, halogen, C1-C4 –
alkyl, C1-C4 – haloalkyl, C1-C4 – alkoxy,
C1-C4 – alkylthio and C1-C4 –
haloalkylthio, and
(b) carbamates of the formula
in which T is CH or N, n is 0, 1 or 2 and R
is halogen, C1-C4 – alkyl or C1-C4 –
July 5, 2006– ‫ט' בתמוז התשס"ו‬
haloalkyl, where the radicals R may be
different if n is 2, in a synergistically
effective amount.
1166
__________
]11[]21[
143465
‫רזונטור אקוסטי בעל נפח פתוח מחורר‬
]54[
ACOUSTIC RESONATOR WITH
BORED OPEN VOLUME
]22[
]31[
]51[
]71[
22.07.1999
98/15243
]32[ 30.11.1998
]33[ FR
Int. Cl.8 G10C 003/06, G10D 013/08, G10K 011/04
PICA-SOUND INTERNATIONAL,
FRANCE
MARC CHARBONNEAUX, PIERRE
PICCALUGA, PATRICE
MORCHAIN, CLAUDE-ANNIE
PERRICHON
WO/2000/033291
DR. MARK FRIEDMAN LTD.,
,‫ד"ר מרק פרידמן ושות‬
BEIT SAMUELOFF, 7 HAOMANIM
‫ תל אביב‬,7 ‫בית שמואלוב רח' האומנים‬
STREET
TEL AVIV
]72[
]87[
]74[
[57] An apparatus, comprising: a sound
generator; and an acoustic resonator means
for improving the sound emitted by the
sound generator, wherein the acoustic
resonator means comprises: a base; one or
more walls attached to or integral with the
1167
base; a first opening in at least one of said
walls; and a second opening in said base,
wherein the first opening is located near
the base, the one or more walls define an
open cavity, and the base of the resonator
is mounted on a hollow stem.
July 5, 2006– ‫ט' בתמוז התשס"ו‬
__________
]11[]21[
143578
‫צמדים שומניים המכילים חומר‬
‫עם פעילות ביולוגית המכיל‬
‫קבוצת אמינו ותכשירי רוקחות‬
‫המכילים אותם‬
]54[
LIPIDIZED CONJUGATES CONTAINING
AN AMINO GROUP-CONTAINING
BIOLOGICALLY ACTIVE SUBSTANCE
AND PHARMACEUTICAL
COMPOSITIONS CONTAINING THE
SAME
]22[
]31[
]51[
09.12.1999
60/111784
]32[
10.12.1998
]33[ US
Int. Cl.8 A61K 031/195, 038/11, 047/48, C07C 229/10, 235/76, 323/54, 323/60, C07D
307/60, C07K 007/16, 014/62
UNIVERSITY OF SOUTHERN CALIFORNIA,
U.S.A.
WO/2000/034236
WOLFF, BREGMAN AND GOLLER,
,‫ ברגמן וגולר‬,‫וולף‬
19B KEREN HAYESOD ST.
,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
P.O.B. 1352,
‫ירושלים‬
JERUSALEM 91013
]71[
]87[
]74[
[57] Compounds of the formula
July 5, 2006– ‫ט' בתמוז התשס"ו‬
1168
in which R2 is selected from the group
consisting of hydrogen, halo, alkyl, or aryl,
wherein the alkyl or aryl are optionally
substituted with one or more alkoxy,
alkanoyl, nitro, cycloalkyl, alkenyl,
alkynyl, acyloxy, alkyl or halogen atoms;
R3 is a lipophilic group; one of R4 and R5
is a biologically active amino group
containing substance selected from the
group consisting of an amine-containing
drug, a natural or unnatural amino acid, a
peptide and a protein and the other of R4
and R5 is OR6 where R6 is selected from
the group consisting of hydrogen, an alkali
metal and a negative charge; X is oxygen
or sulfur; Y is a bridging natural or
unnatural amino acid; n is zero or 1; and m
is an integer from zero to 10.
__________
]11[]21[
]54[
HAZARD MONITOR FOR
SURGICAL TOURNIQUET
SYSTEMS
]22[
]31[
]51[
]71[
02.03.1999
210221
]32[ 10.12.1998
Int. Cl.8 A61B 005/00, 005/04
WESTERN CLINICAL
ENGINEERING LTD., CANADA
JAMES A. MCEWEN
WO/2000/033748
JEREMY M. BEN-DAVID & CO.
LTD.,
HAR HOTZVIM HI-TECH PARK,
P.O. BOX 45087,
JERUSALEM 91450
]72[
]87[
]74[
[57] A hazard monitor (2) for surgical
tourniquet systems, comprising: pressure
transducing means for detecting a pressure
in a pneumatic tourniquet cuff (4); power
monitoring means for monitoring the
supply of electricity to an electrically
powered component of a tourniquet
1169
143583
‫בקר סיכון עבור מערכות חבישה‬
]33[
US
,‫דוד ושות' בע"מ‬-‫ בן‬.‫ירמיהו מ‬
‫ ירושלים‬,45087 .‫ד‬.‫ ת‬, ‫הר חוצבים‬
instrument, wherein the tourniquet
instrument is connectable pneumatically to
the tourniquet cuff to supply pressurized
gas to the cuff, thereby producing a
pressure in the cuff; and hazard detection
means (26) responsive to the pressure
transducing means and the power
July 5, 2006– ‫ט' בתמוז התשס"ו‬
monitoring means for producing an alarm
signal (28) if a pressure is detected in the
tourniquet cuff when electricity is not
supplied to the electrically powered
component of the tourniquet instrument.
__________
]11[]21[
]54[
PHOSPHOLIPID COMPLEXES OF
PROANTHOCYANIDIN A2 AS
ANTIATHEROSCLEROTIC
AGENTS
]22[
]31[
]51[
]71[
]87[
]74[
13.12.1999
MI98A002732 ]32[ 18.12.1998
Int. Cl.8 A61K 035/00, C07F 009/10
INDENA S.P.A., ITALY
WO/2000/037062
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.BOX 4060,
TEL AVIV 61040
143751
‫קומפלכסים פוספוליפידים של‬
‫ הפועלים כחומרים‬A2 ‫פרואנטוציאנידין‬
‫נגד טרשת עורקים‬
]33[
IT
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
[57] Phospholipid complexes of
proanthocyanidin A2.
__________
July 5, 2006– ‫ט' בתמוז התשס"ו‬
1170
]11[]21[
143841
,‫ תהליכים להכנתן‬,‫תרכובות אמיד‬
‫ותכשירי רוקחות המכילים אותן‬
]54[
AMIDE COMPOUNDS ,
PROCESSES FOR THEIR
PREPARATION AND
PHARMACEUTICAL
COMPOSITIONS CONTAINING
THE SAME
]22[
]31[
]51[
]71[
06.01.2000
PP8180
]32[ 14.01.1999
]33[ AU
Int. Cl.8 A61K 031/445, A61P 025/28, C07D 211/58, 211/96
FUJISAWA PHARMACEUTICAL
CO., LTD., JAPAN
WO/2000/042011
WOLFF, BREGMAN AND GOLLER,
,‫ ברגמן וגולר‬,‫וולף‬
19B KEREN HAYESOD ST.
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
P.O.B. 1352,
JERUSALEM 91013
]87[
]74[
[57] A compound of the formula
wherein R1 is lower alkanoyl, lower
alkoxycarbonyl, benzoyl, benzoyl
substituted with halo (lower) alkoxy, lower
alkylsulfonyl, phenylsulfonyl,
phenylsulfonyl substituted with halogen, or
cyclo (lower) alkylcarbonyl; R2 is phenyl,
phenyloxy or phenylamino, each phenyl of
which may be substituted with halogen; A
is a single bond;
E is ethylene;
X is CH;
Y is –NH-;
Q is –CO- or –SO2-; and
R3 and R4, taken together, form ethylene;
and pharmaceutically acceptable salts
thereof.
__________
]11[]21[
1171
143888
July 5, 2006– ‫ט' בתמוז התשס"ו‬
]54[
PERISTALTIC COMPRESSORS
SUITABLE FOR RELAXATION
FREE COMPRESSION OF
POLARIZED GAS
]22[
]31[
]51[
]71[
20.12.1999
98/16366
]32[ 23.12.1998
Int. Cl.8 F04B 035/00, 045/073, 045/08
CENTRE NATIONAL DE LA
RECHERCHE SCIENTIFIQUE (C.N.R.S), FRANCE
WO/2000/039464
SANFORD T.COLB & CO.,
P.O.B. 2273,
REHOVOT
]87[
]74[
[57] A peristaltic compressor (10)
suitable for the relaxation-free
compression of polarized gas including a
rotor (14) driven by a motor (20) provided
with a plurality of rollers (12) and at least a
tube (16), wherein the rotor and the
pumping tubes are placed in a
‫מדחסי צינור גמיש המותאמים לדחיסה‬
‫לארפויה של גז מקוטב‬
]33[
FR
,,'‫ קולב ושות‬.‫סנפורד ט‬
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
depressurized chamber (11) inside which
prevails a lower pressure than the
atmospheric pressure, characterized in that
the motor is formed by at least one tube
fed by a pressurized fluid, driving into
rotation a peristaltic rotor provided with
rollers, coupled with the pumping rotor.
__________
]11[]21[
July 5, 2006– ‫ט' בתמוז התשס"ו‬
143913
1172
‫פיתוח ופריסה עבור רשתות באמצעות‬
USSD –‫ ו‬SMS
]54[
WEB DEVELOPMENT AND
DEPLOYMENT USING SMS AND
USSD
]22[
]31[
]51[
]71[
]72[
]74[
21.06.2001
599534
]32[ 23.06.2000
]33[ US
Int. Cl.8 H04L 012/64, 029/06, H04Q 007/22
COMVERSE LTD.
‫ תל אביב‬,‫קומברס בע"מ‬
ARIEL CATTAN, TOMER BASHAN
‫ תומר בשן‬,‫אריאל קטן‬
G.E. EHRLICH (1995) LTD.,
,‫) בע"מ‬1995( ‫ארליך‬.‫אי‬.‫ג'י‬
AYALON TOWER 15TH FLOOR
,11 ‫ רחוב מנחם בגין‬15 ‫מגדל אילון קומה‬
11 MENACHEM BEGIN STREET
‫רמת גן‬
52521 RAMAT GAN
[57] A communication system,
comprising: a protocol converting
controller that receives a first upstream
mobile terminal message having a mobile
terminal communication protocol and
converts the first upstream mobile terminal
message into a first upstream Internet
message having an Internet protocol,
wherein the protocol converting controller
receives the first upstream mobile terminal
messages, selects a first upstream Internet
address corresponding to the first upstream
mobile terminal message, and generates
the first upstream Internet message based
on the first upstream Internet address,
wherein the upstream Internet message is
supplied to an Internet application,
wherein the protocol converting controller
determines if the first upstream mobile
terminal message is part of an existing
session with the Internet application,
wherein, when the first upstream mobile
terminal message is part of the existing
session, the protocol converting controller
selects a first selected Internet address as
the first upstream Internet address, and
wherein, when the first upstream mobile
terminal message is not part of the existing
session, the protocol converting controller
selects a second selected Internet address
as the first upstream Internet address.
__________
]11[]21[
1173
144003
July 5, 2006– ‫ט' בתמוז התשס"ו‬
)‫ [(הטרוציקלי‬4 – ‫ – פנ יל‬3 ‫תולדות של‬
‫ – מותמר‬7 – ‫אתוקסי] – בנזיל – קומרין‬
‫ותכשירי רוקחות המיכלים תרכובות לאו‬
‫לויסות קולטני אסטרוגן‬
]54[
DERIVATIVES OF 3 - PHENYL - 4 [(HETEROCYCLIC) ETHOXY] BENZYL
- 7 - SUBSTITUTED - COUMARINS,
AND PHARMACEUTICAL
COMPOSITIONS COMPRISING
SAID
COMPOUNDS FOR MODULATION
OF ESTROGEN RECEPTORS
]22[
]31[
]51[
]71[
30.12.1999
60/114472
]32[ 30.12.1998
]33[ US
Int. Cl.8 A61K 031/352, A61P 015/00, C07D 311/12, 405/00
SIGNAL PHARMACEUTICALS,
INC., U.S.A.
WO/2000/039120
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.BOX 4060,
TEL AVIV 61040
]87[
]74[
[57] Estrogen agonist and antagonist
compounds of the formula
or a stereoisomer, prodrug or
pharmaceutically acceptable salt thereof,
wherein:
n is 0, 1, 3 or 4;
p is 0, 1 or 2;
R1 is an unsubstituted or substituted C6-12
aryl, C7-12 arylalkyl, C3-12 heterocycle or
C4-16 heterocyclealkyl;
July 5, 2006– ‫ט' בתמוז התשס"ו‬
R2 is NRaRb wherein Ra and Rb are
independently hydrogen, C1-8 alkyl, C6-12
aryl, or heterocycle, and wherein Ra and Rb
are optionally substituted with up three
substituents independently selected from
C1-6 alkyl, halogen, C1-6 alkoxy, hydroxy
and carboxyl; or R2 is a heterocyclic ring
of the following structure:
1174
wherein
m1 and m2 are independently 0, 1 or 2, and
both m1 and m2 are not 0,
A is CH2, O, S or NH, Z represents 0, 1, 2
or 3 heterocyclic ring substituents selected
from halogen, C1-8 alkyl, C6-12 aryl, C7-12
arylalkyl, C3-12 heterocycle, or C4-16
heterocyclealkyl, and wherein any
hydrogen atoms on the heterocyclic ring
may, taken together with a hydrogen atom
on an adjacent atom of the heterocylic
ring, form a double bond;
R3 is hydrogen, R4, C(=O)R4, c(=O)OR4,
CONHR4, CONR4R5, or SO2NR5R5; R4
and R5 are independently C1-8 alkyl, C6-12
aryl, C7-12 aralkyl, or a five- or sixmembered heterocycle containing up to
two heteroatoms selected from O, NR6 and
S(O)q, wherein each of the above groups is
optionally substituted with one to three
substituents independently selected from
R7 and q is 0, 1 2;
R6 is hydrogen or C1-4 alkyl; and
R7 is hydrogen, halogen, hydroxy, C1-6
alkyl, C1-4 alkoxy, C1-4 acyloxy, C1-4 thio,
C1-4 alkylsulfinyl, C1-4 alkylsulfonyl,
(hydroxy) C1-4 alkyl, C6-12 aryl, C7-12
aralkyl, COOH, CN, CONHOR8,
SO2NHR8, NH2, C1-4 alkylamino, C1-4
dialkylamino, NHSO2R8, NO2, or a five –
or six-membered heterocycle, where each
occurrence of R8 is independently C1-6
alkyl.
__________
]11[]21[
]54[
METHOD FOR IGNITING A
PLASMA INSIDE A PLASMA
PROCESSING REACTOR
]22[
]31[
]51[
]71[
28.12.1999
223692
]32[ 30.12.1998
Int. Cl.8 H01J 037/32
LAM RESEARCH CORPORATION,
U.S.A.
WO/2000/039838
WOLFF, BREGMAN AND GOLLER,
19B KEREN HAYESOD ST.
P.O.B. 1352,
JERUSALEM 91013
]87[
]74[
[57] A plasma processing reactor (300)
for processing a substrate (314)
comprising: a process chamber (302)
within which a plasma can be both ignited
and substained for said processing; an RF
1175
144022
‫שיטה להצתת פלסמה בתוך מגוב‬
‫עיבודפלסמה‬
]33[
US
,‫ ברגמן וגולר‬,‫וולף‬
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
power source having an RF frequency; an
inductive coil (310) coupled to said RF
power source and configured to generate
an electric field inside of said process
chamber, and a magnetic field producing
July 5, 2006– ‫ט' בתמוז התשס"ו‬
apparatus (330) configured to produce a
magnetic field inside said process chamber
in proximity of said electric field, said
magnetic field effective to promote
ignition of said plasma within said process
chamber, said magnetic field activated to
ignite said plasma and deactivated after
said plasma is ignited within the process
chamber.
__________
]11[]21[
144028
‫הרכבים המכילים משנה תגובה חיסונית‬
‫לטיפול בדיספלסיה צווארית‬
]54[
FORMULATIONS COMPRISING
AN IMMUNE RESPONSE
MODIFIER FOR TREATMENT OF
CERVICAL DYSPLASIA
]22[
]31[
]51[
]71[
07.01.2000
60/115253
]32[ 08.01.1999
]33[ US
Int. Cl.8 A61K 031/435, A61P 015/00, C07D 213/72, 471/04, 471/14, 498/04, 513/04
3M INNOVATIVE PROPERTIES
COMPANY, U.S.A.
WO/2000/040228
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.BOX 4060,
TEL AVIV 61040
]87[
]74[
[57] Use of an immune response modifier
(IRM) compound selected from the
July 5, 2006– ‫ט' בתמוז התשס"ו‬
1176
group consisting of imidazoquinoline
amines, imidazolpyridine amines, 6, 7fused cycloalkylimidazopyridine amines,
1, 2-bridged imidazoquinoline amines,
thiazolo and oxazolo-quinolineamines and
pyridinamines, imidazonaphthyridine and
tetrahydroimidazonaphthyridine amines in
the manufacture of a pharmacecutical
formulation for the treatment of cervical
dysplasia, said formulation additionally
comprising: a fatty acid; a preservative
system; and a carbomer.
__________
]11[]21[
144112
‫מדכאים טריסיקליים של פולימרסים של‬
)ADP–Ribose(
POLY
]54[
TRICYCLIC INHIBITORS OF
POLY (ADP-RIBOSE)
POLYMERASES
]22[
]31[
]51[
10.01.2000
60/115431
]32[ 11.01.1999
]33[ US
Int. Cl.8 A61K 031/395, A61P 003/00, 009/00, 017/00, 019/00, 025/00, 029/00,
035/00, C07D 471/06, 487/06, 519/06
AGOURON PHARMACEUTICALS,
INC., U.S.A.
STEPHEN EVAN WEBBER, S.
STACIE CANAN-KOCH,
JAYASHREE TIKHI, LARS HENRIK
THORESEN
WO/2000/042040
DR. MARK FRIEDMAN LTD.,
,‫ד"ר מרק פרידמן ושות‬
BEIT SAMUELOFF, 7 HAOMANIM
‫ תל אביב‬,7 ‫בית שמואלוב רח' האומנים‬
STREET
TEL AVIV
]71[
]72[
]87[
]74[
[57] A compound selected from the
group consisting of:
1177
July 5, 2006– ‫ט' בתמוז התשס"ו‬
‫‪1178‬‬
‫ט' בתמוז התשס"ו –‪July 5, 2006‬‬
or a pharmaceutically acceptable salt
of solvate thereof.
__________
]11[]21[
]54[
AIR CONDITIONING SYSTEM
]22[
]51[
]71[
]72[
]74[
03.07.2001
Int. Cl.8 F24F 003/14
AGAM ENERGY SYSTEMS LTD.
GAD ASSAF
WOLFF, BREGMAN AND GOLLER,
19B KEREN HAYESOD ST.
P.O.B. 1352,
JERUSALEM 91013
[57] An air conditioning system for an
environment (2) within an enclosure (4),
said system comprising: an air/water
cooling tower (6) in fluid flow
communication, via a water/brine heat
exchanger (10), with a brine/air heat
exchanger (8), and a brine regenerator (16)
1179
144119
‫מערכת למיזוג אוויר‬
‫ הוד השרון‬,‫אג"מ מערכות אנרגיה בע"מ‬
‫גד אסף‬
,‫ ברגמן וגולר‬,‫וולף‬
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
in fluid flow communication with said
brine/air heat exchanger; said water/brine
heat exchanger being located outside said
brine/air heat exchanger, and said brine/air
heat exchanger having an air outlet (62) to
said enclosure and an air inlet (60).
July 5, 2006– ‫ט' בתמוז התשס"ו‬
________
]11[]21[
144209
‫מערכת עבור משוב ואומדן הנוצרים על ידי‬
‫קהילה‬
]54[
SYSTEM FOR COMMUNITYGENERATED FEEDBACK AND
RATINGS
]22[
]31[
]51[
]71[
]74[
09.07.2001
624165
]32[ 24.07.2000
]33[ US
Int. Cl.8 G06F 019/00, H04L 012/28, H04M 011/00
COMVERSE LTD.
‫ תל אביב‬,‫קומברס בע"מ‬
G.E. EHRLICH (1995) LTD.,
,‫) בע"מ‬1995( ‫ארליך‬.‫אי‬.‫ג'י‬
AYALON TOWER 15TH FLOOR
,11 ‫ רחוב מנחם בגין‬15 ‫מגדל אילון קומה‬
11 MENACHEM BEGIN STREET
‫רמת גן‬
52521 RAMAT GAN
[57] A network system for providing and
retrieving feedback and rating information
in real-time in regard to products, services,
or the providers of products or services,
based on one or more user-defined
communities of interest, said network
system comprising: a data input device
operable to facilitate entry of data by a
user; a user location determiner operable to
determine the location of said user; a first
interface operable to provide feedback
categories and rating information, said
categories and rating information being
associated with said data entered by said
user; a second interface operable to
retrieve feedback and rating information
and present them to said user; a feedback
and rating information server in
communication with said data input device
operable to process said data; a
communities server in communication
with said data input device and operable to
provide details about communities with
which said user defines a relationship; and
a location server in communication with
said user location determiner and operable
to provide details of providers of products
and services in relation to said user
location.
__________
July 5, 2006– ‫ט' בתמוז התשס"ו‬
1180
]11[]21[
]54[
METHOD AND EQUIPMENT FOR
PAIRING OR CABLING TWO OR
MORE THREADS WHEN
ENTERING TEXTILE MACHINES
USED FOR KNITTED GOODS,
HOSIERY AND THE LIKE
]22[
]31[
07.02.2000
BS99A000010 ]32[ 09.02.1999
BS99A000022
12.03.1999
BS99A000094
08.10.1999
Int. Cl.8 D03J 001/04, D04B 035/22
MEMMINGER-IRO GMBH,
GERMANY
WO/2000/047805
DR. YITZHAK HESS & PARTNERS,
279 HAYARKON STREET
P.O.B. 6451
TEL AVIV 61063
]51[
]71[
]87[
]74[
[57] A method of pairing two or more
threads (11, 12) for use in a textile
machine for knitted goods, hosiery and the
like, wherein the two or more threads are
paired and cabled to form a resulting
paired or cabled thread, said method
comprising the steps of transporting two or
more individual threads to be paired or
cabled to a pairing or cabling device (A)
associated with a work station of said
textile machine, pairing or cabling said
144221
‫שיטה וציוד עבור זיווג או קליעה של שניים‬
‫או יותר חוטים בזמן הכנסה במכונות‬
,‫טקסטיל בשימוש עבור טובין סרוגים‬
‫גרביונים ודומיהם‬
]33[
IT
IT
IT
,‫ עו"פ‬,‫ד"ר יצחק הס ושותפיו‬
‫ תל אביב‬,6451 .‫ד‬.‫ ת‬, 279 ‫רחוב הירקון‬
individual threads by pneumatic or
mechanical action in said pairing or
cabling device (A) to form a single
resulting paired thread (10) and furnishing
said single resulting paired thread to said
textile machine at a controlled thread
tension, wherein at least one of said
individual threads and the single resulting
paired thread are passed through thread
feeding means.
__________
1181
July 5, 2006– ‫ט' בתמוז התשס"ו‬